ELVN (Enliven Therapeutics) Sale Of Property, Plant, Equipment : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Sale Of Property, Plant, Equipment?

Enliven Therapeutics's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Enliven Therapeutics gained $0.00 Mil from selling property, plant, and equipment. Enliven Therapeutics's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), Enliven Therapeutics gained the same money from selling property, plant, and equipment in Sep. 2024 ($0.00 Mil).

Enliven Therapeutics Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Enliven Therapeutics's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics Sale Of Property, Plant, Equipment Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Sale Of Property, Plant, Equipment

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Sale Of Property, Plant, Equipment	Get a 7-Day Free Trial									-	-	-	-	-

Enliven Therapeutics Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Enliven Therapeutics Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Sale Of Property, Plant, Equipment

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Executives

Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Rahul D. Ballal	director, officer: President & CEO	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Mika K Derynck	director	C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107